Evidence map›Paper›PMID 35582009›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2021

Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance.

Federica Bessone, Chiara Dianzani, Monica Argenziano, Luigi Cangemi, Rita Spagnolo, Federica Maione, Enrico Giraudo, Roberta Cavalli

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Federica BessoneDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Chiara DianzaniDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Monica ArgenzianoDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Luigi CangemiDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Rita SpagnoloDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Federica MaioneLaboratory of Tumor microenvironment, Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Italy.
Enrico GiraudoDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
Roberta CavalliDepartment of Drug Science and Technology, University of Turin, Turin 10125, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Albumindoxorubicindrug resistanceglycol chitosannanoparticlesovarian and breast cancer

Identifiers

PMID35582009
PMCPMC9019188
OpenAlexW3101529593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.